My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Cognition Therapeutics, Inc.

< Previous 1 2 3 Next >
Analyses from Cognition’s Positive Phase 2 ‘SHINE’ Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease will be Presented in a Podium Presentation at CTAD
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB)
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common Dementia
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics to Report Second Quarter 2024 Financial Results
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics’ Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer’s Patients
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at 8:30am ET on Monday July 29, 2024
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Results from Cognition Therapeutics’ Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease Accepted for Presentation at AAIC
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer’s Disease on April 12, 2024
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Announces Closing of $11.5 Million Public Offering of Common Stock
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Announces Proposed Public Offering of Common Stock
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer’s Disease Studies
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics to Present at the TD Cowen Health Care Conference
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
New Publication Identifies Key Proteins Involved in Amyloid Oligomer Binding and Supports Mechanism of CT1812
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics CEO Issues Letter to Shareholders
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Releases New Episode of “Conversations” Podcast Recorded at CTAD with Quantitative EEG Experts, Drs Willem de Haan and Philip Scheltens
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Presents Preclinical Data Identifying Pathways Impacted by Sigma-2 Receptor Modulators in Alzheimer’s and Parkinson’s Diseases
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Completes Enrollment in Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
Cognition Therapeutics and Collaborators at Yale and ACTC Announce Oral Late-breaking Presentation on the START Study in Early Alzheimer’s Disease at CTAD
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Tickers CGTX
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.